MARKET

OMCL

OMCL

Omnicell Com
NASDAQ

Real-time Quotes | Nasdaq Last Sale

112.99
+3.27
+2.98%
After Hours: 112.99 0 0.00% 16:02 05/27 EDT
OPEN
110.95
PREV CLOSE
109.72
HIGH
113.97
LOW
110.86
VOLUME
252.41K
TURNOVER
0
52 WEEK HIGH
187.29
52 WEEK LOW
104.32
MARKET CAP
4.99B
P/E (TTM)
75.83
1D
5D
1M
3M
1Y
5Y
Here's Why I Think Omnicell (NASDAQ:OMCL) Might Deserve Your Attention Today
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
Simply Wall St. · 3d ago
Catalent's (CTLT) Latest Facility Expansion to Boost Capacity
Catalent's (CTLT) latest site expansion is expected to significantly boost its business.
Zacks · 5d ago
Reasons to Retain Catalent (CTLT) Stock in Your Portfolio
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.
Zacks · 5d ago
What's in the Cards for Medtronic (MDT) in Q4 Earnings?
Medtronic's (MDT) Cardiovascular business is expected to have gained share in both high and low power devices in Q4.
Zacks · 5d ago
Reasons to Retain DaVita (DVA) Stock in Your Portfolio For Now
Investors remain optimistic about DaVita (DVA) due to strength in its DaVita Kidney Care and impressive overseas growth.
Zacks · 05/20 13:03
Catalent's (CTLT) New Launch to Enhance Gene Therapy Development
Catalent's (CTLT) latest launch is expected to provide a reliable, reproducible and scalable path to clinic to its customers.
Zacks · 05/19 16:34
NextGen Healthcare (NXGN) Q4 Earnings Miss Mark, Revenues Beat
NextGen Healthcare's (NXGN) fiscal fourth-quarter earnings reflect strength in its Recurring revenues.
Zacks · 05/18 15:27
Reasons to Add Patterson Companies (PDCO) Stock to Your Portfolio
Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.
Zacks · 05/18 14:48
More
No Data
Learn about the latest financial forecast of OMCL. Analyze the recent business situations of Omnicell Com through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

11.11%Strong Buy
66.67%Buy
22.22%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average OMCL stock price target is 163.38 with a high estimate of 190.00 and a low estimate of 130.00.
High190.00
Average163.38
Low130.00
Current 112.99
EPS
Actual
Estimate
0.270.540.811.08
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 550
Institutional Holdings: 50.95M
% Owned: 115.29%
Shares Outstanding: 44.20M
TypeInstitutionsShares
Increased
129
2.14M
New
64
1.10M
Decreased
169
2.44M
Sold Out
27
233.55K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+3.80%
Healthcare Equipment & Supplies
+2.75%
Key Executives
Chairman/Director/President/Chief Executive Officer
Randall Lipps
Chief Financial Officer/Executive Vice President
Peter Kuipers
Chief Human Resource Officer/Executive Vice President
Christine Mellon
Executive Vice President/Chief Administrative Officer
Daniel Johnston
Executive Vice President
Scott Seidelmann
Independent Director
Joanne Bauer
Independent Director
Edward Bousa
Independent Director
Mary Garrett
Independent Director
Vance Moore
Independent Director
Mark Parrish
Independent Director
Bruce Scott
Independent Director
Robin Seim
Independent Director
Sara White
No Data
No Data
About OMCL
Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming the pharmacy care delivery model through automation designed to replace manual, error-prone processes, combined with a single, cloud-based platform and advanced services offerings. Its point-of-care automation solutions are designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Company's Omnicell Interface Software provides interface and integration between its medication-use products or its supply products and a healthcare facility’s in-house information management systems. Its Central Pharmacy IV Compounding Service offers a comprehensive service model inclusive of IV robotic technology, data analytic tools, and clinical support for insourced sterile compounding programs.

Webull offers kinds of Omnicell, Inc. stock information, including NASDAQ:OMCL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OMCL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OMCL stock methods without spending real money on the virtual paper trading platform.